The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients

Summary

To assess the effects of two doses of synthetic peptide construction 3 ( SPC3 ) on HIV-1 plasma levels (as measured by RNA PCR Amplicor) and on lymphocyte subsets in patients with initial viral load above 10,000 copies/ml. To study the safety of SPC3 and the kinetics of HIV-1 plasma level changes.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications